Showing results (281-290 of 318) with videos related to

Sort By:
Pageof 32
The Lancet. Oncology|November 12, 2022
Fluorouracil and dose-dense adjuvant chemotherapy in patients with early-stage breast cancer (GIM2): end-of-study results from a randomised, phase 3 trialLucia Del Mastro, Francesca Poggio, Eva Blondeaux, et al.
Cancers|April 3, 2021
Baseline Characteristics and Outcomes of Cancer Patients Infected with SARS-CoV-2 in the Lombardy Region, Italy (AIOM-L CORONA): A Multicenter, Observational, Ambispective, Cohort StudySerena Di Cosimo, Barbara Tagliaferri, Daniele Generali, et al.
Therapeutic Advances in Medical Oncology|December 22, 2023
Peripheral blood lymphocytes predict clinical outcomes in hormone receptor-positive HER2-negative advanced breast cancer patients treated with CDK4/6 inhibitorsEmma Zattarin, Luigi Mariani, Alice Menichetti, et al.
European Journal of Cancer (Oxford, England : 1990)|May 16, 2022
Persistence of long-term COVID-19 sequelae in patients with cancer: An analysis from the OnCovid registryAlessio Cortellini, Ramon Salazar, Alessandra Gennari, et al.
Eclinicalmedicine|May 31, 2023
Prognostic and clinical impact of the endocrine resistance/sensitivity classification according to international consensus guidelines for advanced breast cancer: an individual patient-level analysis from the Mammella InterGruppo (MIG) and Gruppo Italiano Mammella (GIM) studiesMatteo Lambertini, Eva Blondeaux, Giancarlo Bisagni, et al.
Journal of the National Cancer Institute. Monographs|June 12, 2015
International Expert Consensus on Primary Systemic Therapy in the Management of Early Breast Cancer: Highlights of the Fifth Symposium on Primary Systemic Therapy in the Management of Operable Breast Cancer, Cremona, Italy (2013)Vito Amoroso, Daniele Generali, Thomas Buchholz, et al.
Critical Reviews in Oncology/Hematology|June 8, 2025
The evolving landscape of hormone receptor-positive/HER2-negative metastatic breast cancer (EVOLVE): An Italian Delphi consensus reportFederica Miglietta, Maria Grazia Razeti, Aldo Caltavituro, et al.
Oncotarget|January 8, 2019
Correction 2: Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: new lessons for clinical practice from the EVA studyMarina Cazzaniga, Claudio Verusio, Mariangela Ciccarese, et al.
Seminars in Cancer Biology|January 21, 2015
Broad targeting of angiogenesis for cancer prevention and therapyZongwei Wang, Charlotta Dabrosin, Xin Yin, et al.
Journal of the National Cancer Institute|August 10, 2020
Serial Analysis of Circulating Tumor Cells in Metastatic Breast Cancer Receiving First-Line ChemotherapyMark Jesus M Magbanua, Laura H Hendrix, Terry Hyslop, et al.
Pageof 32